# Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

> **NCT03575208** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)**

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** hepatitis B immune globulin (HBIg)
- **DRUG:** Pegylated interferon alfa (pegIFN)

## Key facts

- **NCT ID:** NCT03575208
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02-13
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow/Insufficient accrual
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575208, "Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03575208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*